WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 2 fonti

Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

Raccontata da

morningstar.com

medpagetoday.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo2 g fa

Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

medpagetoday.com23 h fa

Targeted Combo Boosts PFS in BRAF-Mutant Metastatic Colorectal Cancer

Adding encorafenib and cetuximab to chemotherapy backbone also prolonged overall survival

Leggi questa versione → originale

Timeline cronologica

domenica 31 maggio 2026·morningstar.com
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
lunedì 1 giugno 2026·medpagetoday.com
Targeted Combo Boosts PFS in BRAF-Mutant Metastatic Colorectal Cancer
Adding encorafenib and cetuximab to chemotherapy backbone also prolonged overall survival